Navigation Links
Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement
Date:4/20/2008

NEW YORK and WINNERSH, England, April 21 /PRNewswire/ -- Paul Capital Healthcare and Vernalis plc (LSE: VER) today announced that they have signed a financing agreement relating to frovatriptan, Vernalis' product for the treatment of migraine. Under the agreement, Vernalis will receive approximately euro 18.4 million in cash from Paul Capital Healthcare and, in return, Paul Capital Healthcare will receive approximately 90 per cent of Menarini's payments to Vernalis under their exclusive license and supply agreement for the commercialization of frovatriptan in Europe and certain other territories. Vernalis will continue to supply Menarini with frovatriptan active pharmaceutical ingredient.

Frovatriptan is currently approved for the acute treatment of migraine in Europe, the United States, Canada and seven Central American countries.

"Earlier this year, Vernalis restructured its operations to focus on its innovative discovery programs and to advance its promising pipeline of development stage products to the point at which they can be partnered. This transaction with Paul Capital Healthcare secures significant, non-dilutive funds for Vernalis, giving us the platform to rebuild new shareholder value in the medium term," said Tony Weir, CFO, Vernalis.

Dr. Ken Macleod, a partner at Paul Capital Healthcare, said: "Migraine affects about 10 percent of people and leads to billions of dollars in lost productivity each year. After extensively evaluating both the clinical and commercial data for frovatriptan, we believe this drug is positioned to capture a growing share of the market for migraine therapies. Growth capital is the hallmark of the companies and products in which Paul Capital Healthcare invests, and provides a compelling rationale for adding our investment in Vernalis and frovatriptan to our portfolio of investments."

About Paul Capital Partners and Paul Capital Healthcare

Through its funds, Paul Capital Healthcare is one
'/>"/>

SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. SPO Medical Retains American Capital Ventures for Investor Relations Services
2. MichBio Will Host Workshop on Capital Formation Prior to April 22 Annual Meeting
3. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
4. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
5. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
6. Biotech Avoids Fall Out From Tough Quarter for Capital Markets
7. Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
8. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
9. Pharmasset Receives $10 Million of Working Capital
10. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...NTA CRUZ, Calif., Nov. 24 Two more...enter, the nation,s leading online job board and c...Northwestern and Columbia University are now membe...cience training Institutions. ,, The job board,...ates in the life sciences. While there are hundred...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 /PRNews...DCGN ) today announced that it has received notice...company,s common stock will be,suspended as of Nov...h the,Securities and Exchange Commission, which wi...sdaq, unless the company files an appeal to the Na...
(Date:11/24/2009)... Health care employment grew by 29,000 jo...to show consistent growth during the U.S. recessio... in trouble, and health systems are coming closer ...ad of just administrators. , ...yment continued growing in October despite the she...
(Date:11/24/2009)... SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- NOD Pharma...mark Office (PTO) has allowed the patent applicati...nology. , NOD technology is a highly effi... into bio-adhesive nano-particles to enable oral d...ons. NOD technology is a platform technology,that ...
Breaking Biology Technology:Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4
...chem Laboratories, Inc., a leading research-based ...Drug Products to the pharmaceutical industry, with...ce the recent addition of Dr. Chris Huber as Direc...s to the table over 15 years experience in the pha...oping process technology for API manufacturing of ...
...Biosciences Corporation (Nasdaq: MATK ) announce...cond quarter of fiscal 2009 on June 3, 2009, at ap...g the release, at 4:45 p.m. ET Martek will conduct...nvestors. All interested parties may listen to th...ite at http://investors.martek.com . , , An ...
...ault Corporation is pleased to announce notice of ...folio. U.S. Patent Application #10/005,415, entit...age, Retrieval & Analysis of a Large Number of...78.6, entitled " Archive & Analysis System and...ent U.S. Patent #7,142,987. Taken together, these...
Other Biology Technology:Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development 2GenVault Receives Four Critical U.S. and E.U. Patent Allowances for Key Biosample Management Technologies 2
(Date:11/24/2009)...al Toxicology (ACMT) have signed an agreement to c...edical Toxicology (JMT), the official journal of ...sly published by the University of Pennsylvania Pr...international, peer-reviewed journal, is dedicated...toxicology. The quarterly journal focuses on the ...
(Date:11/24/2009)...crets of the earth,s history locked in its icy dep...e information on the environments that have been s...Now, a team of researchers from nine institutions ...0 million dollars by the National Science Foundati...lly. These scientists will drill through the West ...
(Date:11/24/2009)...search on bacterial communities throughout six lar...poral patterns, suggesting that scientists could u...mate change in the polar regions. The study, publi... Academy of Sciences Early Edition, shows that ba...hronously over time, correlating with seasonal shi...
Breaking Biology News(10 mins):Springer and the American College of Medical Toxicology to work together 2LSU gets to the bottom of things -- in Antarctica 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2Depression May Lead to More Preemies Among Blacks 49006 1Depression May Lead to More Preemies Among Blacks 49006 2Nuvo Research and Covidien sign U S license and development agreement for Pennsaid 28R 29 and Pennsaid Plus 28R 29 49003 1Nuvo Research and Covidien sign U S license and development agreement for Pennsaid 28R 29 and Pennsaid Plus 28R 29 49003 2Nuvo Research and Covidien sign U S license and development agreement for Pennsaid 28R 29 and Pennsaid Plus 28R 29 49003 3Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once Daily INFERGEN 28R 29 with Ribavirin in Hepatitis C Virus Treatment Failures 12641 1Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once Daily INFERGEN 28R 29 with Ribavirin in Hepatitis C Virus Treatment Failures 12641 2Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once Daily INFERGEN 28R 29 with Ribavirin in Hepatitis C Virus Treatment Failures 12641 3Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once Daily INFERGEN 28R 29 with Ribavirin in Hepatitis C Virus Treatment Failures 12641 4
... (DECEMBER 26, 2008) A team of scientists from th...S) has reported a rapid recovery of coral reefs in...vastated coastal regions throughout the Indian Oce...am, working in conjunction with the Australian Res...Studies (ARCCoERS) along with government, communit...
... organic crop production is increasing around the ...ding environmental benefits and decreasing the amo...ter. While organics gain popularity with consumers...allenges, especially managing and reducing invasiv...etroleum-based materials, have been used extensive...
...mployers in the landscape industry revealed the im...udents with technical knowledge, practical applica...s the skills necessary to solve complex landscape ...ccess. , With the rapid advancement of technology...e to present students with virtual case studies vi...
Other Biology News:4 years after tsunami: Corals stage comeback 24 years after tsunami: Corals stage comeback 3Organic plant waste proves effective weed control for citrus trees 2Organic plant waste proves effective weed control for citrus trees 3Web-based case studies help students develop career skills 2
Methadone ELISA Kit, Single from Bio-Quant Inc.
Rat Prolactin EIA Kit from Cayman Chemical
Z Amphetamine ELISA Kit, Single from Bio-Quant Inc.
Mumps IgG ELISA Kit, Single from Bio-Quant Inc.
Biology Products: